Q32 Bio Inc.
QTTB
$1.64
-$0.02-1.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -224.35% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -224.35% | -- | -- |
| Cost of Revenue | 60.86% | 21.21% | 11.27% | -- | -- |
| Gross Profit | -14.87% | -0.21% | -144.91% | -- | -- |
| SG&A Expenses | 44.87% | 81.86% | 75.44% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.63% | 58.88% | 48.82% | -- | -- |
| Operating Income | -12.27% | -36.98% | -154.92% | -- | -- |
| Income Before Tax | -31.59% | 10.36% | -62.36% | -- | -- |
| Income Tax Expenses | -148.74% | -148.74% | 1,975.61% | -- | -- |
| Earnings from Continuing Operations | -30.34% | 11.18% | -66.68% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.34% | 11.18% | -66.68% | -- | -- |
| EBIT | -12.27% | -36.98% | -154.92% | -- | -- |
| EBITDA | -12.40% | -37.40% | -157.57% | -- | -- |
| EPS Basic | 96.27% | 98.04% | 0.23% | -- | -- |
| Normalized Basic EPS | 94.64% | 96.84% | 23.48% | -- | -- |
| EPS Diluted | 96.46% | 93.24% | -9.16% | -- | -- |
| Normalized Diluted EPS | 94.67% | 96.40% | 22.72% | -- | -- |
| Average Basic Shares Outstanding | 2,268.95% | 2,571.30% | 210.42% | -- | -- |
| Average Diluted Shares Outstanding | 1,331.33% | 2,667.41% | 226.79% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |